MedTrace Logo

Pre Transplantation Melanoma

NCT04217382 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2021-12-10

No results posted yet for this study

Summary

Melanoma incidence is increase in global population and number of transplantation also. However immunosuppressor increase recurrence risk of melanoma.

There are more and more cases of eligible patients to transplant with an antecedent of melanoma. There is no guideline yet.

Main objective is survival time without melanoma recurrence in this population to do guideline of time limit or not between melanoma and transplantation by stage.

Conditions

  • Malignant Melanoma

Interventions

OTHER

patient with melanoma pre transplantation

survival time without melanoma recurrence

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Emilie DUCROUX, MD · Service de Dermatologie, Hôpital Edouard Herriot, Lyon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-27
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04217382 on ClinicalTrials.gov